Press Release
November 18, 2026

Goodwin Advises Omniose on Acquisition by AstraZeneca

The Life Sciences and Private Equity teams advised Omniose on its acquisition by AstraZeneca. Goodwin previously represented Omniose in its entry into a research collaboration and merger option agreement with AstraZeneca in January 2024, which granted AstraZeneca the right to acquire Omniose. Following a productive three-year exclusive research collaboration, AstraZeneca exercised the option and completed the acquisition in November 2026, making Omniose a wholly owned subsidiary of AstraZeneca and part of its Infectious Disease Unit.

The acquisition brings Omniose’s proprietary bioconjugation platform and expertise into AstraZeneca, complementing existing capabilities and supporting its preclinical vaccine programs.

Omniose is an early-stage biotechnology company developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform.

The Goodwin team was led by Ed Amer, Beni Surpin, Shannyn Henke, Dan Karelitz, Jim Mattus, Peter Yang, Scott Zilora, Matt Denny, and Kingsley Taft.

For more information on the deal, please read the press release and coverage in Fierce Biotech.